Biodefense Market Size, Share & Trends Analysis Report By Product (Anthrax, Smallpox, Botulism, Radiation/Nuclear), By Region (North America, Europe, APAC), And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 4 Business Days
Biodefense Market Growth & Trends
The global biodefense market size is expected to reach USD 22.8 billion by 2030, and it is set to expand at 5.0% CAGR from 2022 to 2030, according to a new report by Grand View Research, Inc. Biodefense can be briefly defined as a set of comprehensive measures (identification, planning, and preparedness) undertaken to restore the biosecurity of a country.
It aims to tackle key biological threats or infectious diseases that can be easily used as a bioweapon to instigate social unrest and bioterrorism. Biological threats can be natural, accidental, or deliberate in origin and in all forms, present a grave threat. Factors like the presence of favorable government initiatives, increasing investment by private players, and the growing prevalence of various viral agents are fueling market growth.
Previous incidents of bioterrorism caused by viral agents like anthrax, smallpox, and botulism have made Biodefense a major focus area. The increased need for advancements for countries to defend themselves against grave threats remains the primary driver of growth. In 2017, the Centers for Disease Control and Prevention (CDC) stated that they had tracked more than 170 unique diseases, and outbreaks in more than 190 countries.
According to WHO, around 6,50,000 people die of respiratory diseases associated with seasonal flu annually. Repeated outbreaks of Zika and Ebola virus have coerced state governments to construct and strategize biodefense programs. These new programs will assist in planning and response during future outbreaks.
In 2018, the U.S. government announced a national biodefense strategy to manage the risk of biological threats. The new strategy can detect and contain bio-threats at its source, while simultaneously promoting biomedical innovation, and improving emergency response. These factors are expected to boost market growth.
Biodefense Market Report Highlights
Biodefense Market Growth & Trends
The global biodefense market size is expected to reach USD 22.8 billion by 2030, and it is set to expand at 5.0% CAGR from 2022 to 2030, according to a new report by Grand View Research, Inc. Biodefense can be briefly defined as a set of comprehensive measures (identification, planning, and preparedness) undertaken to restore the biosecurity of a country.
It aims to tackle key biological threats or infectious diseases that can be easily used as a bioweapon to instigate social unrest and bioterrorism. Biological threats can be natural, accidental, or deliberate in origin and in all forms, present a grave threat. Factors like the presence of favorable government initiatives, increasing investment by private players, and the growing prevalence of various viral agents are fueling market growth.
Previous incidents of bioterrorism caused by viral agents like anthrax, smallpox, and botulism have made Biodefense a major focus area. The increased need for advancements for countries to defend themselves against grave threats remains the primary driver of growth. In 2017, the Centers for Disease Control and Prevention (CDC) stated that they had tracked more than 170 unique diseases, and outbreaks in more than 190 countries.
According to WHO, around 6,50,000 people die of respiratory diseases associated with seasonal flu annually. Repeated outbreaks of Zika and Ebola virus have coerced state governments to construct and strategize biodefense programs. These new programs will assist in planning and response during future outbreaks.
In 2018, the U.S. government announced a national biodefense strategy to manage the risk of biological threats. The new strategy can detect and contain bio-threats at its source, while simultaneously promoting biomedical innovation, and improving emergency response. These factors are expected to boost market growth.
Biodefense Market Report Highlights
- The anthrax segment dominated the market in 2022. These bioagents can last longer in the environment, and are released with ease, posing a high potential risk
- The other segment is expected to register the highest CAGR during the forecast period. This segment includes potential threats such as zika, Ebola, and Marburg’s virus. The rising incidents of related outbreaks remain the key growth driver
- North America is expected to dominate the global market during the forecast period, owing to the presence of high federal funding, technological advancements, and growing awareness among the population
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective -
1.10.2 Objective -
1.10.3 Objective -
1.10.4 Objective -
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 BIODEFENCE MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Segmentation And Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Presence Of Favorable Government Initiatives In The U.S.
3.2.2.1 Biodefense Funding In Fy 2016 - 2021 By Federal Agency
3.2.2.2 Emergency Use Authorization Of Medical Products
3.2.2.3 Project Bioshield Act
3.2.2.4 Growing Investment From Private Players
3.2.3 Growing Prevalence Of Various Agents Such As Ebola Virus, Zika Virus, Flu, And Others
3.2.4 Market Restraint Analysis
3.2.4.1 Low Market Penetration In Developing And Underdeveloped Countries
3.3 Penetration & Growth Prospect Mapping
3.4 Biodefence: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s
3.4.2 Pestel Analysis
3.5 Biodefense Competitive Scenario, 2015
3.5.1 Biological Defense
3.5.1.1 Biological Defense: Product Pipeline
3.5.2 Chemical Defense
3.5.2.1 Chemical Defense: Product Pipeline
3.5.3 Nuclear/Radiological Defense
3.5.3.1 Nuclear/Radiological Defense: Product Pipeline Analysis
CHAPTER 4 BIODEFENCE MARKET: PRODUCT SEGMENT ANALYSIS
4.1 Biodefence: Agent Market Share Analysis, 2022 & 2030
4.2 Anthrax
4.2.1 Biodefense Against Anthrax Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3 Smallpox
4.3.1 Biodefense Against Smallpox Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4 Botulism
4.4.1 Biodefense Against Botulism Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5 Radiation/Nuclear
4.5.1 Biodefense Against Radiation/Nuclear Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.2 Others
4.5.2.1 Other Biodefense Products Market, 2018 - 2030 (USD Million)
CHAPTER 5 BIODEFENCE MARKET: REGIONAL ANALYSIS
5.1 Biodefence: Regional Market Share Analysis, 2022 & 2030
5.2 North America
5.2.1 North America Biodefence Market, 2018 - 2030 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. Biodefence Market, 2018 - 2030 (USD Million)
5.2.3 Canada
5.2.3.1 Canada Biodefence Market, 2018 - 2030 (USD Million)
5.3 Europe
5.3.1 Europe Biodefence Market, 2018 - 2030 (USD Million)
5.3.2 U.K.
5.3.2.1 U.K. Biodefence Market, 2018 - 2030 (USD Million)
5.3.3 Germany
5.3.3.1 Germany Biodefence Market, 2018 - 2030 (USD Million)
5.3.4 France
5.3.4.1 France Biodefence Market, 2018 - 2030 (USD Million)
5.3.5 Italy
5.3.5.1 Italy Biodefence Market, 2018 - 2030 (USD Million)
5.3.6 Spain
5.3.6.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
5.3.7 Denmark
5.3.7.1 Denmark Biodefence Market, 2018 - 2030 (USD Million)
5.3.8 Sweden
5.3.8.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
5.3.9 Norway
5.3.9.1 Norway Biodefence Market, 2018 - 2030 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific Biodefence Market, 2018 - 2030 (USD Million)
5.4.2 China
5.4.2.1 China Biodefence Market, 2018 - 2030 (USD Million)
5.4.3 India
5.4.3.1 India Biodefence Market, 2018 - 2030 (USD Million)
5.4.4 Japan
5.4.4.1 Japan Biodefence Market, 2018 - 2030 (USD Million)
5.4.5 Australia
5.4.5.1 Australia Biodefence Market, 2018 - 2030 (USD Million)
5.4.6 Thailand
5.4.6.1 Thailand Biodefence Market, 2018 - 2030 (USD Million)
5.4.7 South Korea
5.4.7.1 South Korea Biodefence Market, 2018 - 2030 (USD Million)
5.5 Latin America
5.5.1 Latin America Biodefence Market, 2018 - 2030 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil Biodefence Market, 2018 - 2030 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico Biodefence Market, 2018 - 2030 (USD Million)
5.5.4 Argentina
5.5.4.1 Argentina Biodefence Market, 2018 - 2030 (USD Million)
5.6 MEA
5.6.1 MEA Biodefence Market, 2018 - 2030 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa Biodefence Market, 2018 - 2030 (USD Million)
5.6.3 Saudi Arabia
5.6.3.1 Saudi Arabia Biodefence Market, 2018 - 2030 (USD Million)
5.6.4 UAE
5.6.4.1 UAE Biodefence Market, 2018 - 2030 (USD Million)
5.6.5 Kuwait
5.6.5.1 Kuwait Biodefence Market, 2018 - 2030 (USD Million)
CHAPTER 6 COMPANY PROFILES
6.1.1 Xoma Corporation
6.1.1.1 Company Overview
6.1.1.2 Financial Performance
6.1.1.3 Product Benchmarking
6.1.1.4 Strategic Initiatives
6.1.2 Altimmune, Inc.
6.1.2.1 Company Overview
6.1.2.2 Financial Performance
6.1.2.3 Product Benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Emergent Biosolutions Inc.
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.3.4 Strategic Initiatives
6.1.4 Dynavax Technologies Corporation
6.1.4.1 Company Overview
6.1.4.2 Financial Performance
6.1.4.3 Strategic Initiatives
6.1.5 Siga Technologies, Inc.
6.1.5.1 Company Overview
6.1.5.2 Financial Performance
6.1.5.3 Product Benchmarking
6.1.5.4 Strategic Initiatives
6.1.6 Elusys Therapeutics, Inc.
6.1.6.1 Company Overview
6.1.6.2 Financial Performance
6.1.6.3 Product Benchmarking
6.1.6.4 Strategic Initiatives
6.1.7 Ichor Medical Systems
6.1.7.1 Company Overview
6.1.7.2 Financial Performance
6.1.7.3 Product Benchmarking
6.1.7.4 Strategic Initiatives
6.1.8 Dynport Vaccine Company Llc
6.1.8.1 Company Overview
6.1.8.2 Financial Performance
6.1.8.3 Product Benchmarking
6.1.8.4 Strategic Initiatives
6.1.9 Cleveland Biolabs
6.1.9.1 Company Overview
6.1.9.2 Financial Performance
6.1.9.3 Product Benchmarking
6.1.9.4 Strategic Initiatives
6.1.10 Bavarian Nordic
6.1.10.1 Company Overview
6.1.10.2 Financial Performance
6.1.10.3 Product Benchmarking
6.1.10.4 Strategic Initiatives
6.1.11 Ology Bioservices
6.1.11.1 Company Overview
6.1.11.2 Financial Performance
6.1.11.3 Product Benchmarking
6.1.11.4 Strategic Initiatives
6.1.12 Alnylam Pharmaceuticals, Inc.
6.1.12.1 Company Overview
6.1.12.2 Financial Performance
6.1.12.3 Product Benchmarking
6.1.12.4 Strategic Initiatives
1.1 Market Segmentation & Scope
1.1.1 Product
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective -
1.10.2 Objective -
1.10.3 Objective -
1.10.4 Objective -
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 BIODEFENCE MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Segmentation And Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.2 Presence Of Favorable Government Initiatives In The U.S.
3.2.2.1 Biodefense Funding In Fy 2016 - 2021 By Federal Agency
3.2.2.2 Emergency Use Authorization Of Medical Products
3.2.2.3 Project Bioshield Act
3.2.2.4 Growing Investment From Private Players
3.2.3 Growing Prevalence Of Various Agents Such As Ebola Virus, Zika Virus, Flu, And Others
3.2.4 Market Restraint Analysis
3.2.4.1 Low Market Penetration In Developing And Underdeveloped Countries
3.3 Penetration & Growth Prospect Mapping
3.4 Biodefence: Market Analysis Tools
3.4.1 Industry Analysis - Porter’s
3.4.2 Pestel Analysis
3.5 Biodefense Competitive Scenario, 2015
3.5.1 Biological Defense
3.5.1.1 Biological Defense: Product Pipeline
3.5.2 Chemical Defense
3.5.2.1 Chemical Defense: Product Pipeline
3.5.3 Nuclear/Radiological Defense
3.5.3.1 Nuclear/Radiological Defense: Product Pipeline Analysis
CHAPTER 4 BIODEFENCE MARKET: PRODUCT SEGMENT ANALYSIS
4.1 Biodefence: Agent Market Share Analysis, 2022 & 2030
4.2 Anthrax
4.2.1 Biodefense Against Anthrax Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.3 Smallpox
4.3.1 Biodefense Against Smallpox Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.4 Botulism
4.4.1 Biodefense Against Botulism Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5 Radiation/Nuclear
4.5.1 Biodefense Against Radiation/Nuclear Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.2 Others
4.5.2.1 Other Biodefense Products Market, 2018 - 2030 (USD Million)
CHAPTER 5 BIODEFENCE MARKET: REGIONAL ANALYSIS
5.1 Biodefence: Regional Market Share Analysis, 2022 & 2030
5.2 North America
5.2.1 North America Biodefence Market, 2018 - 2030 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. Biodefence Market, 2018 - 2030 (USD Million)
5.2.3 Canada
5.2.3.1 Canada Biodefence Market, 2018 - 2030 (USD Million)
5.3 Europe
5.3.1 Europe Biodefence Market, 2018 - 2030 (USD Million)
5.3.2 U.K.
5.3.2.1 U.K. Biodefence Market, 2018 - 2030 (USD Million)
5.3.3 Germany
5.3.3.1 Germany Biodefence Market, 2018 - 2030 (USD Million)
5.3.4 France
5.3.4.1 France Biodefence Market, 2018 - 2030 (USD Million)
5.3.5 Italy
5.3.5.1 Italy Biodefence Market, 2018 - 2030 (USD Million)
5.3.6 Spain
5.3.6.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
5.3.7 Denmark
5.3.7.1 Denmark Biodefence Market, 2018 - 2030 (USD Million)
5.3.8 Sweden
5.3.8.1 Spain Biodefence Market, 2018 - 2030 (USD Million)
5.3.9 Norway
5.3.9.1 Norway Biodefence Market, 2018 - 2030 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific Biodefence Market, 2018 - 2030 (USD Million)
5.4.2 China
5.4.2.1 China Biodefence Market, 2018 - 2030 (USD Million)
5.4.3 India
5.4.3.1 India Biodefence Market, 2018 - 2030 (USD Million)
5.4.4 Japan
5.4.4.1 Japan Biodefence Market, 2018 - 2030 (USD Million)
5.4.5 Australia
5.4.5.1 Australia Biodefence Market, 2018 - 2030 (USD Million)
5.4.6 Thailand
5.4.6.1 Thailand Biodefence Market, 2018 - 2030 (USD Million)
5.4.7 South Korea
5.4.7.1 South Korea Biodefence Market, 2018 - 2030 (USD Million)
5.5 Latin America
5.5.1 Latin America Biodefence Market, 2018 - 2030 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil Biodefence Market, 2018 - 2030 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico Biodefence Market, 2018 - 2030 (USD Million)
5.5.4 Argentina
5.5.4.1 Argentina Biodefence Market, 2018 - 2030 (USD Million)
5.6 MEA
5.6.1 MEA Biodefence Market, 2018 - 2030 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa Biodefence Market, 2018 - 2030 (USD Million)
5.6.3 Saudi Arabia
5.6.3.1 Saudi Arabia Biodefence Market, 2018 - 2030 (USD Million)
5.6.4 UAE
5.6.4.1 UAE Biodefence Market, 2018 - 2030 (USD Million)
5.6.5 Kuwait
5.6.5.1 Kuwait Biodefence Market, 2018 - 2030 (USD Million)
CHAPTER 6 COMPANY PROFILES
6.1.1 Xoma Corporation
6.1.1.1 Company Overview
6.1.1.2 Financial Performance
6.1.1.3 Product Benchmarking
6.1.1.4 Strategic Initiatives
6.1.2 Altimmune, Inc.
6.1.2.1 Company Overview
6.1.2.2 Financial Performance
6.1.2.3 Product Benchmarking
6.1.2.4 Strategic Initiatives
6.1.3 Emergent Biosolutions Inc.
6.1.3.1 Company Overview
6.1.3.2 Financial Performance
6.1.3.3 Product Benchmarking
6.1.3.4 Strategic Initiatives
6.1.4 Dynavax Technologies Corporation
6.1.4.1 Company Overview
6.1.4.2 Financial Performance
6.1.4.3 Strategic Initiatives
6.1.5 Siga Technologies, Inc.
6.1.5.1 Company Overview
6.1.5.2 Financial Performance
6.1.5.3 Product Benchmarking
6.1.5.4 Strategic Initiatives
6.1.6 Elusys Therapeutics, Inc.
6.1.6.1 Company Overview
6.1.6.2 Financial Performance
6.1.6.3 Product Benchmarking
6.1.6.4 Strategic Initiatives
6.1.7 Ichor Medical Systems
6.1.7.1 Company Overview
6.1.7.2 Financial Performance
6.1.7.3 Product Benchmarking
6.1.7.4 Strategic Initiatives
6.1.8 Dynport Vaccine Company Llc
6.1.8.1 Company Overview
6.1.8.2 Financial Performance
6.1.8.3 Product Benchmarking
6.1.8.4 Strategic Initiatives
6.1.9 Cleveland Biolabs
6.1.9.1 Company Overview
6.1.9.2 Financial Performance
6.1.9.3 Product Benchmarking
6.1.9.4 Strategic Initiatives
6.1.10 Bavarian Nordic
6.1.10.1 Company Overview
6.1.10.2 Financial Performance
6.1.10.3 Product Benchmarking
6.1.10.4 Strategic Initiatives
6.1.11 Ology Bioservices
6.1.11.1 Company Overview
6.1.11.2 Financial Performance
6.1.11.3 Product Benchmarking
6.1.11.4 Strategic Initiatives
6.1.12 Alnylam Pharmaceuticals, Inc.
6.1.12.1 Company Overview
6.1.12.2 Financial Performance
6.1.12.3 Product Benchmarking
6.1.12.4 Strategic Initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 U.S. government civilian biodefense funding, by agencies for the years 2017 - 2019 in USD Million.
Table 4 National Institutes of Health Funding for the years 2017 - 2019 in USD Million
Table 5 Travel Associated cases of Zika Virus in the U.S in 2019
Table 6 Ebola Funding to WHO, 2019
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 U.S. government civilian biodefense funding, by agencies for the years 2017 - 2019 in USD Million.
Table 4 National Institutes of Health Funding for the years 2017 - 2019 in USD Million
Table 5 Travel Associated cases of Zika Virus in the U.S in 2019
Table 6 Ebola Funding to WHO, 2019
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Biodefence market snapshot (2022)
Fig. 10 Biodefence market segmentation
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Porter’s five forces analysis
Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 16 Biodefence market product type outlook: Segment dashboard
Fig. 17 Biodefence market: Product movement analysis
Fig. 18 Anthrax market, 2018 - 2030 (USD Million)
Fig. 19 Smallpox market, 2018 - 2030 (USD Million)
Fig. 20 Botulism market, 2018 - 2030 (USD Million)
Fig. 21 Radiation and Nuclear market, 2018 - 2030 (USD Million)
Fig. 22 Others market, 2018 - 2030 (USD Million)
Fig. 23 Regional market: Key takeaways
Fig. 24 Regional outlook, 2022 & 2030
Fig. 25 North America market, 2018 - 2030 (USD Million)
Fig. 26 U.S. market, 2018 - 2030 (USD Million)
Fig. 27 Canada market, 2018 - 2030 (USD Million)
Fig. 28 Europe market, 2018 - 2030 (USD Million)
Fig. 29 U.K. market, 2018 - 2030 (USD Million)
Fig. 30 Germany market, 2018 - 2030 (USD Million)
Fig. 31 France market, 2018 - 2030 (USD Million)
Fig. 32 Italy market, 2018 - 2030 (USD Million)
Fig. 33 Spain market, 2018 - 2030 (USD Million)
Fig. 34 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 35 China market, 2018 - 2030 (USD Million)
Fig. 36 India market, 2018 - 2030 (USD Million)
Fig. 37 Japan market, 2018 - 2030 (USD Million)
Fig. 38 Latin America market, 2018 - 2030 (USD Million)
Fig. 39 Brazil market, 2018 - 2030 (USD Million)
Fig. 40 Mexico market, 2018 - 2030 (USD Million)
Fig. 41 Argentina market, 2018 - 2030 (USD Million)
Fig. 42 MEA market, 2018 - 2030 (USD Million)
Fig. 43 South Africa market, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Biodefence market snapshot (2022)
Fig. 10 Biodefence market segmentation
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Porter’s five forces analysis
Fig. 15 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 16 Biodefence market product type outlook: Segment dashboard
Fig. 17 Biodefence market: Product movement analysis
Fig. 18 Anthrax market, 2018 - 2030 (USD Million)
Fig. 19 Smallpox market, 2018 - 2030 (USD Million)
Fig. 20 Botulism market, 2018 - 2030 (USD Million)
Fig. 21 Radiation and Nuclear market, 2018 - 2030 (USD Million)
Fig. 22 Others market, 2018 - 2030 (USD Million)
Fig. 23 Regional market: Key takeaways
Fig. 24 Regional outlook, 2022 & 2030
Fig. 25 North America market, 2018 - 2030 (USD Million)
Fig. 26 U.S. market, 2018 - 2030 (USD Million)
Fig. 27 Canada market, 2018 - 2030 (USD Million)
Fig. 28 Europe market, 2018 - 2030 (USD Million)
Fig. 29 U.K. market, 2018 - 2030 (USD Million)
Fig. 30 Germany market, 2018 - 2030 (USD Million)
Fig. 31 France market, 2018 - 2030 (USD Million)
Fig. 32 Italy market, 2018 - 2030 (USD Million)
Fig. 33 Spain market, 2018 - 2030 (USD Million)
Fig. 34 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 35 China market, 2018 - 2030 (USD Million)
Fig. 36 India market, 2018 - 2030 (USD Million)
Fig. 37 Japan market, 2018 - 2030 (USD Million)
Fig. 38 Latin America market, 2018 - 2030 (USD Million)
Fig. 39 Brazil market, 2018 - 2030 (USD Million)
Fig. 40 Mexico market, 2018 - 2030 (USD Million)
Fig. 41 Argentina market, 2018 - 2030 (USD Million)
Fig. 42 MEA market, 2018 - 2030 (USD Million)
Fig. 43 South Africa market, 2018 - 2030 (USD Million)
